Top Markets
#1 Black Phoenix Black Phoenix +732.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.80%
#3 TENDIES TENDIES +22.99%
#4 THORChain THORChain +18.96%
#5 Biconomy Biconomy +18.30%
#6 MetaDAO MetaDAO +16.83%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +16.29%
#8 Pons Pons +16.01%
#9 Moolah Moolah +15.93%
#10 THORChain Yield THORChain Yield +13.92%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Zai Lab Limited Zai Lab Limited

Zai Lab Limited

ZLAB
Classificação em ações #5163
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a... Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Preço da ação
$26.03
Última sincronização: 2026-08-26
Valor de mercado
$2.94B
Variação (1 dia)
-0.55%
Variação (1 ano)
-20.07%
País
CN
Negociar Zai Lab Limited (ZLAB)

Categoria

Healthcare
Histórico de preços das ações de Zai Lab Limited (ZLAB)
Preço de fecho mais alto: $25.27 em 2026-08-01

Preço de fecho mais baixo: $27.89 em 2017-09-01
Histórico de preços das ações da Zai Lab Limited de 2017 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 19.83%
2025 -32.96%
2024 -1.60%
2023 -15.44%
2022 -50.77%
2021 -44.11%
2020 193.25%
2019 87.31%
2018 -9.94%
2017 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.38 41.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 47.75%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $148.35 491.02%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.41 -12.81%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $764.47 7.08%
CH